

Forum Review

Novel Role of Protein Disulfide Isomerase in the Regulation of NADPH Oxidase Activity: Pathophysiological Implications in Vascular Diseases

FRANCISCO R. M. LAURINDO,¹ DENISE C. FERNANDES,¹ ANGÉLICA M. AMANSO,¹
LUCIA R. LOPES,² and CÉLIO X. C. SANTOS¹

ABSTRACT

Vascular cell NADPH oxidase complexes are key sources of signaling reactive oxygen species (ROS) and contribute to disease pathophysiology. However, mechanisms that fine-tune oxidase-mediated ROS generation are incompletely understood. Besides known regulatory subunits, upstream mediators and scaffold platforms reportedly control and localize ROS generation. Some evidence suggest that thiol redox processes may coordinate oxidase regulation. We hypothesized that thiol oxidoreductases are involved in this process. We focused on protein disulfide isomerase (PDI), a ubiquitous dithiol disulfide oxidoreductase chaperone from the endoplasmic reticulum, given PDI's unique versatile role as oxidase/isomerase. PDI is also involved in protein traffic and can translocate to the cell surface, where it participates in cell adhesion and nitric oxide internalization. We recently provided evidence that PDI exerts functionally relevant regulation of NADPH oxidase activity in vascular smooth muscle and endothelial cells, in a thiol redox-dependent manner. Loss-of-function experiments indicate that PDI supports angiotensin II-mediated ROS generation and Akt phosphorylation. In addition, PDI displays confocal co-localization and co-immunoprecipitates with oxidase subunits, indicating close association. The mechanisms of such interaction are yet obscure, but may involve subunit assembling stabilization, assistance with traffic, and subunit disposal. These data may clarify an integrative view of oxidase activation in disease conditions, including stress responses. *Antioxid. Redox Signal.* 10, 1101–1113.

INTRODUCTION

REDOX PATHWAYS ADD AN IMPORTANT DIMENSION to cell signaling networks regulating physiological and pathological events, particularly cardiovascular disorders such as hypertension (16, 99). However, mechanisms providing fine-tuning of redox equilibrium are complex and yet incompletely understood. Indeed, it has been shown that redox signaling can occur in the absence of overall changes in redox status of the major intracellular reductants glutathione or thioredoxin (37), and thus can be separated from oxidative stress, which is a disruption

of redox signaling requiring some type of cellular adaptation (49). Accordingly, most intra- and extracellular redox buffer pairs are not in equilibrium, suggesting their independent regulation (49), and further indicating that oxidative stress is more complex than a simple overall imbalance between oxidants and antioxidants in favor of the former. In turn, oxidative stress activates vicious signaling circuits in several disease conditions, not only as a result of direct free radical-mediated damage to biomolecules, but—perhaps mostly—from disordered activation and/or expression of subcellular signaling targets due to excessive, uncompensated, or decompartmentalized

¹Vascular Biology Laboratory, Heart Institute (InCor), University of São Paulo School of Medicine; and ²Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, Brazil.

reactive oxygen species (ROS) generation (49). A simultaneous requisite and corollary of this notion is the fact that cellular ROS generation is mainly a nonaccidental controlled enzymatic process. Thus, understanding how such enzymatic sources of ROS are regulated at the structural and cellular physiological levels is likely important to provide a more elaborated picture of the redox pathophysiology of vascular diseases. Among several enzymatic systems, vascular isoforms of the phagocyte NADPH oxidase complex appear to be the most relevant source of basal as well as agonist-induced signaling ROS (11, 39, 63). In this review, we discuss some novel mechanisms underlying NADPH oxidase regulation, with emphasis in the role of the endoplasmic reticulum (ER) redox chaperone protein disulfide isomerase.

The oxidase complex possesses a modular multisubunit structure, with catalytic flavin-binding Nox subunits and a number of regulatory subunits. Expression of each of them varies according to the specific vascular cell type, so that the term "Vascular NADPH Oxidase" actually stands for unequal proportions of several types of enzyme complexes belonging to each cell type (Table 1). Nox isoforms have been ascribed an important role in several pathophysiological conditions such as hypertension, atherosclerosis, restenosis after injury, and diabetic vasculopathy (reviewed in refs. 11, 16, 39, 63). Molecular structural aspects of NADPH oxidase and the known differences among Nox isoforms regarding their expression profile, type of ROS produced, and subcellular localization are reviewed in detail in excellent references (11, 39, 63).

On the other hand, comparatively less is known about mechanisms underlying the regulation of NADPH oxidase complex activity and expression. Certainly, first-order regulatory steps are the identity and intrinsic characteristics of agonist-specific Nox isoforms occurring in each vascular cell type, as well as expression, subcellular traffic and phosphorylation of known regulatory subunits (such as p22phox and p47phox or its analogs). A more refined knowledge of structural aspects of these subunits is likely to provide further insights into subcellular physiology of the oxidase, as has recently been shown for the alternatively spliced variants of the p47phox analog NOXO-1, which can account for distinct Nox complex locations within

cells (103). In general, exposure to agonists is associated with increased mRNA and protein expression of such oxidase subunits, which seems to account for increased ROS generation (63). It is generally agreed that, upon activation, vascular oxidase undergoes minor, if any, further assembling of stock and newly-synthesized subunits, as the complexes seem to pre-assemble very early within the ER-secretory pathway (63, 64). Particularly, p22phox and Nox1/Nox4 are already assembled in resting cells (4, 11, 63). Independently of assembling, protein traffic appears to be important for oxidase activation. In fact, oxidase activation in endothelial (100) or smooth muscle cells (64) is simultaneous to shift of subunit(s) from perinuclear region to membranes. Moreover, ROS production from NADPH oxidase agonists is blocked by the Golgi disruptor agent brefeldin-A (CX Santos CX *et al.*, unpublished observations). Similarly, the phagocyte oxidase undergoes traffic among subcellular vesicular compartments (54), in accordance with the recent description of p67phox-binding JFC1 protein, which appears to be involved in 3'-phosphoinositide-dependent vesicle translocation to plasma membrane (15).

It seems underappreciated that the particular multisubunit architecture of the oxidase, together with the many subcellular regulatory mechanisms discussed so far, composes a system particularly likely to display a stochastic behavior (50). Therefore, despite the desired precision of signaling and the danger of uncontrolled oxidant generation, an intrinsic degree of random variation among cells would not be unexpected. Yet, it is apparent that the attained and necessarily high degree of specificity in NADPH oxidase-dependent ROS-mediated signaling is not sufficiently explained only by selection of specific subunits (11). What is yet missing includes a better definition of mechanisms, coordinated at a cellular level, that restrict such ROS generation spatially and temporally to specific subcellular microdomains and post-translational mechanisms that account for activation of particular Nox isoforms (105). Several upstream mediators and associated proteins (reviewed in refs. 11 and 17) were described to interact with oxidase activation and might help confer targeted specificity. Furthermore, important advances in this regard were provided by a series of recent works (reviewed in ref. 105) describing scaffold-like pro-

TABLE 1. VASCULAR NAD(P)H OXIDASE

	<i>Catalytic subunits (basal expression)</i>			<i>Associated regulatory subunits</i>	<i>Main cellular effect</i>
	<i>EC</i>	<i>VSMC</i>	<i>Fib</i>		
Nox 1	+	++	0/+	p22 phox Noxo 1 Noxa 1	Proliferation Migration
Nox 2	++	0	+++	p47 phox (?) p22 phox p47 phox p67 phox p40 phox (?)	Proliferation Migration Inflammation
Nox 4	+++	++	+	p22 phox	Differentiation Apoptosis
Nox 5	+	++	(?)	p22 phox	Ca ²⁺ -mediated responses

EC, endothelial cell; Fib, fibroblast; VSMC, vascular smooth muscle cell.

The relative amount (+ to +++) represents semiquantitative estimates from the several references cited in text.

Rac 1 regulates activity of Nox 1 and Nox 2 complexes, while its role for Nox 4 and Nox 5 is unclear.

tein platforms capable of localizing NADPH oxidase-dependent ROS signals. In this context, the redox and thiol-dependent regulation of NADPH oxidase and the proposed role of protein disulfide isomerase, discussed in the following sections, add further light into the orchestration of all such regulatory mechanisms.

REDOX REGULATION OF NADPH OXIDASE

There is some evidence, albeit indirect, that nonphagocytic NADPH oxidase is regulated by redox processes. Exogenous administration of H_2O_2 triggers oxidase activity (66) and has been documented to induce expression and activity of Nox4 isoform (19, 69). After exposure of VSMC to agonists such as angiotensin II, ROS production occurs in two waves (89). The initial ROS production involves Rac activation due to the action of PKC and later to c-Src activation, EGF receptor transactivation, and PI3K activation. The second peak of ROS production is PKC-independent and depends on a more robust sustained phosphorylation of p47phox (11, 17, 89). It can be speculated that these two waves represent activation of distinct Nox isoforms (11). ROS contribute to downstream signaling pathways, including translation initiation (84), which eventually feedback positively on further oxidase-dependent ROS generation (11, 17). In fact, when the first ROS wave is abrogated by specific signaling antagonists, the second wave is also decreased (89). An analogous phenomenon occurs in an endothelial cell line after exposure to thrombin. In this case, antagonism of the initial wave of ROS generation, occurring after 15 min, was found to prevent the later increase in p22phox mRNA expression and its concomitant sustained ROS production 3 h later (24). Redox regulation of the oxidase provides a feed-forward activation mechanism able to recruit in a redox-dependent form mediators that act upstream to a later more sustained oxidase activation. In addition, it provides a redox cross-talk mechanism between the stock oxidase subunits and the later increase in expression that is known to sustain oxidase activation.

THIOL REAGENTS AND NADPH OXIDASE

It has been known for several years that the phagocyte NADPH oxidase complex is inhibited by distinct oxidizing or alkylating thiol reagents (20), an effect accompanied by decreased negativity of cytochrome b^{558} reducing potential (8). Inhibition of the oxidase with the dithiol alkylator phenylarsine oxide indicated a role for critical dithiol(s), which were assigned to two target gp91phox cysteines, accessible in resting but not activated neutrophils (23). More recently, our laboratory extended such observations to the vascular oxidase (45). We showed that incubation of cell membrane homogenates with the oxidant diamide or DTNB (5,5'-dithio-bis (2-nitrobenzoic acid), or the alkylator PCMPs (*p*-chloro mercuryphenylsulfonic acid), but not with *N*-ethylmaleimide or glutathione disulfide, led to a strong inhibition of enzyme activity. A less evident inhibition was also found for the reductant *N*-acetylcysteine. Analogous inhibition of the apparent oxidase activity was noted

with such reagents in vascular rings, in a way unrelated to the degree of cellular glutathione depletion. However nonspecific and indirect, these findings collectively suggested a critical role for redox thiols in oxidase activation, which appeared unrelated to changes in overall cellular redox status. In addition, the rapid reversibility of diamide or PCMPs inhibitory effects upon their withdrawal, or with *N*-acetylcysteine, indicated that thiolation was unlikely to explain such effects. This led to the hypothesis of a thiol oxidoreductase-mediated mechanism. In fact, as with other redox-mediated signaling pathways, there are kinetic constraints for accepting an unrestricted, direct spontaneous reaction of ROS with critical protein thiols, given the overall low rate constants (32), some of them shown in Table 2. This possibly results in rates of thiol oxidation or disulfide exchange too low to account for functionally effective signaling. Although the low pKa of critical protein thiols will make such groups much more reactive and mark them as selective targets of oxidants, effective redox regulation may require additional mediation by thiol oxidoreductases, which can accelerate thiol reaction rates by factors up to $\sim 10^4$ and thus might be required as essential players in redox signaling cascades (5, 32, 34, 74).

PROTEIN DISULFIDE ISOMERASE: PROPERTIES OF A SIGNALING THIOL OXIDOREDUCTASE

Considering the thiol oxidoreductases known to exert a role in cell signaling, the thioredoxin superfamily is particularly important and well documented (5, 18, 108, 110). The major characteristic of thioredoxin family is the catalytic dithiol motif CXXC, where X can be a wide range of amino acids. In the case of thioredoxin, the motif is CGPC. Redox properties of the thioredoxin motif, dictated in part but not solely from the amino acid composition, as well as the multiple alpha-beta folds found in the secondary structure, account for the known different properties of several members of this family. Thioredoxin itself (molecular weight 12 kDa) is known as catalytic proton donor for ribonucleotide reductase and is a known subunit of T7 DNA polymerase (18). It acts mostly as a reductase with several cellular roles, particularly apoptosis protection and NF-kappaB (and other transcription factor) binding to DNA (110).

Among the several members of the thioredoxin superfamily, PDI (molecular weight 55 kDa) and its analogs are the only

TABLE 2. RATE CONSTANTS OF ROS AND THIOL REACTIONS (IN $M^{-1} s^{-1}$)

	$O_2^{\bullet-}$	H_2O_2	$ONOO^-$	Reference
Cysteine	$<15^*$	2.9	4.5×10^3	3, 10, 81, 109
GSH	20	0.87	1.3×10^3	81, 88, 109
BSA/HSA	NR	2.26	3.8×10^3	3, 14, 80

*All rate constants were calculated at physiological pH, with exception of Cys/ $O_2^{\bullet-}$, which was at pH 10.9.

NR, no reaction.

Some data were collected from <http://allen.rad.nd.edu/Solnkin2/> site (last accessed 3/15/07).

ones known to catalyze isomerase reactions (*i.e.*, the ordered rearrangement of disulfide bonds through repeated cycles of reductions and oxidations) (18, 25, 30, 74, 108) (Fig. 1). Accordingly, the classic function of PDI is to promote the redox-mediated protein folding at the ER (41), which is PDI's primary location. Oxidizing equivalents for this function are provided to PDI by the ER thiol-containing oxidase Ero-1 (endoplasmic reticulum oxidase-1), which in turn is reoxidized via electron transfer to oxygen, mediated by bound FAD, generating ROS in this process (40, 101, 108). Ero-1-dependent oxidative activity is counteracted and balanced by cytosolic glutathione, suggesting that a shuttle mechanism from cytosol acts to control the ER redox environment (72). However, PDI can also act as a reductase depending on the ambient reducing potential. At the ER, given the relatively oxidizing conditions (GSH/GSSG ratios ~ 2 – 3 :1), PDI acts as an isomerase/oxidase, while outside the ER, at GSH/GSSG ratios >30 – 100 :1, PDI acts mainly as a reductase (74, 108). This significant redox versatility stems from several factors, including the low pKa of the proximal cysteine of the active N-terminal *a* domain. Such pKa of 4.5 renders PDI a much better oxidase than thioredoxin, which has a pKa of 7.1 and is mainly a reductase. Accordingly, the standard reducing potential of PDI is -180 mV, compared to -260 mV for thioredoxin (108). Furthermore, mutation of the active thioredoxin site sequence CGPC to the PDI sequence CGHC renders thioredoxin a 10-fold better oxidant, indicating the importance of a close positively-charged histidine residue capable of promoting thiol ionization, consequently lowering the cysteine pKa (25, 67). A similar effect is also provided by an arginine residue postulated to transiently interact with the catalytic cysteine through secondary folding (62). PDI structure shows several domain modules ordered as *a*-*b*-*b'*-*a'*-*c* (Fig. 2), in which *a* and *a'* are thioredoxin domains bearing the redox-active WCGHC motif, *b* and *b'* are thioredoxin structural folds without the redox motif, possibly related to peptide recognition and binding (25, 30, 41, 74, 98, 108), and *c* a putative Ca^{2+} -binding C-terminal domain, which appears to be less critical in mammalian, as opposed to yeast PDI (98). Redox-active cysteines at the *a* and *a'* domains exist as reduced dithiols or intramolecular or mixed disulfides. Only the *a* and/or *a'* domains are required for PDI's oxidase activity, whereas all four thioredoxin domains are required for more complex isomerizations (108). Elucidation of the crystal structure of PDI has defied several attempts and was solved for yeast PDI only recently (98), showing characteristics likely to be met also by mammalian PDI's. The enzyme has a twisted U-shaped structure, with ac-

tive domains displaying flexibility and facing each other along the arms of the U, while both are attached to a rigid substrate-binding scaffold composed by the *b* domains (98). The *b'* domain at the bottom of the U appears to be the main substrate binding site and, together with its neighborhood, is enriched in hydrophobic residues (Fig. 2). In combination with the overall continuous hydrophobic surface of the PDI molecule, this allows binding of substrates of different sizes and disulfide bond locations. Thus, while specific domains or motifs promoting binding of other proteins to PDI have not been precisely defined, it is likely that surface hydrophobic sequences in such substrates are important (41, 98, 108). In fact, many studies have suggested that protein binding to PDI does not require the redox-active sequences, although such motifs are important to stabilize the binding (53, 73). Moreover, ATPase activity and Ca^{2+} binding may modulate PDI protein binding (42, 83, 108). In yeast, but perhaps less so in mammalian PDI, the *a* domain displays a lower redox potential than the *a'* domain (56, 98), perhaps reflecting the predominant oxidase function of PDI in yeast, which evolved to a more elaborated isomerase function in mammals. PDI also displays a chaperone function, which is independent of the redox-active domains (98). Several (>14) PDI analogues have been described, indicating that PDI is part of a larger protein family variably displaying thiol oxidoreductase, chaperone, and isomerase properties (18, 25, 30). PDI can also display transglutaminase activity, although the importance of this property *in vivo* is unclear (27).

PDI is an abundant protein, able to reach millimolar concentrations within the liver ER (74). In addition, PDI is essential for cell survival even in yeast, so that any substantial decrease in its expression can have profound adverse effects (57, 108). In mammalian cells, PDI expression sustains cell survival, and upregulation of PDI or its novel analogue endo-PDI increases resistance to apoptosis after hypoxia in astrocytes or endothelial cells (38, 95, 96). Such essential physiological role has usually been ascribed to its important role in protein folding. However, an increasing number of functions for PDI are being described, suggesting an important role in cell signaling. PDI displays a KDEL C-terminal sequence characteristic of ER retention, which has been suggested to be required for ER retention of associated proteins (90). The most important examples in this regard are prolyl-4 hydroxylase (the rate-limiting enzyme for collagen biosynthesis) and microsomal triglyceride transfer protein, which are well known to heterodimerize with PDI (74, 108). Such heterodimerization has additionally the functions of preventing protein aggregation (48) and providing




FIG. 1. Thiol redox reactions driven by PDI on peptide/protein substrates containing disulfides, defined as sufficiently close thiol groups either at primary or secondary structure. PDI can display a reductase activity at locations outside the ER in which local redox state is more reducing. In the ER, and potentially in other less reductive microenvironments, PDI tends to act as a thiol oxidase and/or isomerase, reactions that are essential for proper protein folding. However, excessive ER oxidation can cause protein misfolding and aggregation and may inhibit ER-assisted protein degradation (92).




FIG. 2. Schematic representation of PDI structure. (A) Domain organization of mammalian PDI (adapted from ref. 74) showing the five PDI domains *a*, *b*, *b'*, *a'*, and *c*. The redox-active thioredoxin motifs (WCGHC) are located at domains *a* and *a'*. The *b'* domain is the main peptide binding site and the *c* domain contains the carboxy-terminal KDEL endoplasmic reticulum retention signal. (B) Diagram (adapted from refs. 41 and 74) depicting the crystal structure of yeast PDI (98) showing the U-shaped form of the molecule with the active *a* and *a'* domains at the arms of the U, and *b* and *b'* domains at the bottom; arrows indicate the beginning of each domain. The active site thiols are represented as space-filling model.

oligomer assembly stability (55). PDI can also trap other proteins as aggregates [e.g., the oxidase Ero-1 within the ER (77)] or other chaperones in the ER (70) or at the cytosolic side of Sec61 translocon (93). A recently described interesting function of PDI is the redox-mediated stabilization of receptive sites at the MHC-1 peptide-binding groove, allowing functionally relevant selection of optimal peptides during antigen presentation (79).

In addition, it has been well documented that PDI displays active intracellular traffic (97) and is found at the surface of diverse prokaryotic and eukaryotic cells. The mechanisms whereby PDI bypasses the KDEL receptor despite maintaining the KDEL C-terminal sequence are unclear (97, 108). It is also unclear whether PDI leaves the ER through the translocon Sec61 pore (93) and/or via secretory vesicles. In addition, in macrophages and potentially other cells, the ER may itself constitute a part of the endosome–phagosome network, thus carrying PDI, as well as other ER proteins, to such remote locations (21a). PDI seems to be loosely attached via electrostatic charges at the hepatocyte cell membrane and, after its significant rate of secretion, may eventually suffer some reuptake (97). Dithiols constitute ~25% of cell surface thiols (111). Labeling of such cell-surface dithiols indicates about a dozen proteins, including PDI, suggesting that its redox-active site(s) can be well exposed at the cell surface (22, 47). In such location, PDI

appears to favor dithiol reduction, consistent with its role as reductase (47). In addition, PDI is also a major catalyst of transnitrosation reactions mediating nitric oxide internalization from extracellular *S*-nitrosothiols (82, 111). Functions for extracellular PDI have been increasingly explored and may include roles such as cell surface recognition in cell-to-cell contact (83), shedding of L-selectin (9), chemokine receptor-dependent HIV cell internalization (7), and integrin-dependent platelet aggregation/adhesion (12). The latter effect is supported by a number of evidences. Platelet adhesion is inhibited by PDI antagonists, including the specific neutralizing monoclonal antibody RL90 (28, 29, 58, 59). In fact, enzymatic-mediated thiol exchange stabilizes platelet aggregation mediated by integrin $\alpha_2\beta_1$ (60). In addition, integrin β subunits were shown by FRET to physically interact with PDI (12). Furthermore, integrins (e.g., $\alpha_{2b}\beta_3$) carry a CXXC thioredoxin motif (106), and at least some integrins (75), as well as fibronectin (61), exhibit an endogenous thiol isomerase activity, although its function is yet uncertain. PDI involvement with adhesion molecules may be a more general phenomenon, considering its analogous associations with thrombospondin (43) and cognin (78). An analogous effect of cell-surface PDI in the coagulation system was recently described. PDI disables, in an NO-dependent way, tissue factor-induced coagulation by disrupting its critical disulfide bond and activating its factor VII-related signaling branch via protease-activated receptor 2 (PAR2) (1). In addition to its roles at the cell surface, PDI has also important roles in protein traffic and secretion (97) [e.g., binding and export of proteins such as thyroglobulin (21)].

An important situation in which, among several other features, PDI may be overexpressed and undergoes membrane traffic, is the *unfolded protein response (UPR)*, a complex multiple signaling cascade activated by the accumulation of unfolded or incorrectly folded proteins in the ER, potentially induced by altered ER Ca^{2+} transport, reductive stress, disturbed protein glycosylation, or simply an excess of secretory cell activity (86, 91). Accumulation of defective proteins in the ER lumen triggers ER stress, that, if sustained, can lead to apoptosis. In fact, the PDI promoter exhibits two UPR-sensitive sequences (87), and PDI expression in this situation has been linked to the removal of incorrectly folded proteins (71, 92, 93), since PDI assists the retrotranslocation of misfolded proteins to the cytosol for proteasomal degradation (92), in contrast to its analog Erp72, which tends to inhibit this process (33). In some neurodegenerative diseases, PDI S-nitrosation has been shown to abrogate its enzymatic activity and PDI-induced retrotranslocation of defective proteins, leading to ER dysfunction and cell loss (102). On the other hand, at least in the case of familial ALS, PDI appears to counteract the formation of aggregates of mutant SOD1 (6).

ROLE OF PDI IN NADPH OXIDASE REGULATION IN VASCULAR SMOOTH MUSCLE CELLS (VSMC)

Studies from our laboratory have recently provided several data suggesting a relevant role of PDI in the regulation of NADPH oxidase activity in VSMC (46). In general, VSMC ex-

posure to NADPH oxidase agonists such as angiotensin II does not change the already high baseline PDI expression; however, significant shift of PDI location toward the membrane fraction is observed. In isolated membrane homogenates exposed to diverse types of PDI antagonism, a significant (up to ~80%) decrease in NADPH oxidase activity was uniformly observed, irrespective of the method of measuring the oxidase activity, which included EPR (46), lucigenin chemiluminescence (Fig. 3A) and HPLC analysis of dihydroethidium oxidation products (Fig. 3B) (31). Strategies for PDI antagonism included bacitracin, a pharmacological antagonist of PDI oxidoreductase activity (28, 68, 76), a neutralizing anti-PDI antibody, the competitive substrate scrambled RNase (28), or the thiol reagent DTNB, known to inhibit NADPH oxidase (45) as well as PDI (36) activity. Since inhibition of PDI isomerase activity due to bacitracin, anti-PDI antibody, or DTNB is known to involve PDI thiols (28, 36, 68, 76) and all compounds were effective when incubated with membrane fraction after its separation, these results suggest together that PDI co-fractionates with

NAD(P)H oxidase and contributes to assist its activity via thiol redox mechanisms.

More specific evidence in a cellular context was obtained by examining the effects of an antisense oligonucleotide directed against PDI, which induced a decrease (average ~70%) both in baseline and angiotensin II-stimulated NADPH oxidase activity. In addition, the antisense oligonucleotide promoted a marked decrease in VSMC ROS production assessed by dihydroethidium fluorescence (46). Moreover, the antisense oligonucleotide prevented early angiotensin II-mediated phosphorylation of Akt, which is known to be mediated by NADPH oxidase-dependent ROS (104), thus indicating a functional role for PDI-assisted oxidase activation. The refolding isomerase PDI activity, assessed through the rates of scrambled RNase renaturation (108), was increased 5-fold in the membrane homogenate during angiotensin II-induced oxidase activation. Such increase was inhibited by bacitracin or the antisense oligonucleotide against PDI. These data further support a role of thiols in functional PDI interaction with NAD(P)H oxidase.

Results of co-immunolocalization experiments with confocal microscopy provided evidence for a spatial interaction between PDI and the p22phox subunit of NADPH oxidase (46). The PDI antisense oligonucleotide transfection did not visibly change p22phox signals, but decreased PDI signals and their co-localization at baseline and after angiotensin II. In addition, co-localization was also observed with Nox 1 and Nox4, which are the main Nox isoforms expressed in VSMC. Furthermore, PDI immunoprecipitation yielded co-precipitation of NAD(P)H oxidase subunits p22phox (ref. 46 and Fig. 4), Nox1, and Nox 4. Such results were further assessed in HEK293 cells transfected with Nox1, Nox2, and Nox4-yfp coding plasmids. Precipitation of PDI revealed co-precipitation of all three Nox-yfp constructs (46). In all cases, the co-immunoprecipitation was not altered after incubation with angiotensin II, in line with the reported preassembling of p22phox and Nox1/Nox4 already in resting cells (4). In general, the association of PDI with diverse oxidase subunits indicates either direct binding to each Nox, binding to a common regulatory subunit (e.g., p22phox) or to a kinase/phosphatase regulatory domain, or co-migration to a specific cellular microdomain.

In summary, results obtained so far in the VSMC indicate that PDI is associated with the NADPH oxidase complex and exerts a regulation of its activity that exhibits some degree of thiol redox sensitivity, though such redox sensitivity can be indirect. Together, the combination of versatile PDI redox properties, its known role in protein traffic and secretion, and its involvement with relevant signaling cascades open considerable perspectives regarding an integrative knowledge of mechanisms controlling NAD(P)H oxidase activation, and consequently oxidant stress, in the vascular system.

PDI AND NADPH OXIDASE INTERACTION: EVIDENCES IN OTHER CELL TYPES

We have pursued further evidence for a possible role of PDI in oxidase regulation in other cell types, and some ongoing results are already available. In endothelial cells, PDI is strongly





FIG. 3. Effects of diverse PDI antagonists on NADPH oxidase activity in vascular smooth muscle cell (VSMC, from rabbit aorta) membrane homogenates, obtained as described in ref. 46. VSMC were grown to 80–90% confluence in F12 medium supplemented with 10% fetal bovine serum and exposed to angiotensin II (100 nM for 4 h). (A) Effects of PDI inhibitors DTNB (500 μ M), bacitracin (500 μ M), neutralizing anti-PDI antibody (1:100), and scrambled (Scb)RNase (100 μ g/ml), added to VSMC membrane fraction, on NADPH oxidase activity assessed with lucigenin (5 μ M) chemiluminescence. (B) Analogous experiments in VSMC membrane homogenates using a novel NADPH oxidase assay with HPLC analysis of dihydroethidium (DHE) oxidation products (31). Results are expressed as 2-hydroxyethidium (EOH) produced/DHE consumed. ($n = 3-6$; * $p < 0.05$ vs. control baseline; # $p < 0.05$ vs. control + AII; mean \pm SEM).

FIG. 4. Co-immunoprecipitation between protein disulfide isomerase and p22phox subunit in vascular smooth muscle cells (VSMC, from rabbit aorta). VSMC were grown as in Fig. 3 and exposed to angiotensin II (100 nM for 4 h). Cross-linking with Protein G-sepharose beads, antibodies, and immunoprecipitation procedures were similar to ref. 46, except that the precipitate was resolved by a 2-D gel approach, in which pI separation was performed within a pH range of 3 to 10 (corresponding to *black triangles on top of each panel*), followed by standard SDS-PAGE in a 12% gel. Additional controls were run for PDI protein and IgG standards (not shown). (A) and (B) Silver-stained gels of immunoprecipitates obtained with anti-PDI and anti-p22phox antibodies. (C) Western blot analysis of p22phox performed in anti-PDI immunoprecipitates, depicting corresponding band. (D) Reverse immunoprecipitation, in which Western blot analysis of PDI was performed in anti-p22phox immunoprecipitates, again exhibiting co-precipitation.




expressed in the membrane fraction even at baseline and does not exhibit further migration early after exposure to angiotensin II, showing a decreased membrane location and increased total expression at later time points (Fig. 5). This contrasts with VSMC, in which baseline membrane levels are lower, but there is increased migration to membranes upon angiotensin II exposure (46). A functional dependence of oxidase activity on PDI (Fig. 6) is suggested by experiments similar to those reported above for VSMC membrane homogenates in Fig. 3.

Additional ongoing data are being collected in our laborato-

ries for macrophages and human neutrophils (unpublished observations), the latter both in whole cells and in the cell-free system. Such observations indicate that in phagocytes, PDI is also closely associated with NADPH oxidase subunits and exerts a functional regulatory role in ROS generation. Specifically in the neutrophil, PDI co-immunoprecipitates with distinct oxidase subunits at the membrane, as well as p47phox and p67phox in the cytosol (Fig. 7). The phagocyte oxidase is not only important as a well-studied model, but also because macrophages and polymorphonuclear leukocytes play an important

FIG. 5. (A) Western blot analysis of PDI (~55 kDa) in total or membrane-enriched homogenates from rabbit aortic endothelial cells previously exposed to angiotensin II (100 nM, for the indicated time periods). Cells were grown in F12 medium supplemented with 10% fetal bovine serum to 80–90% confluence. (B) NADPH oxidase activity at diverse time points after angiotensin II incubation, assessed with lucigenin (5 μ M) technique. ($n = 3$; $*p < 0.05$ vs. baseline; mean \pm SEM)






FIG. 6. Effects of diverse PDI antagonists on NADPH oxidase activity in rabbit aortic endothelial cell membrane homogenates, obtained as described in ref. 31. Endothelial cells were grown to 80–90% confluence in F12 medium supplemented with 10% fetal bovine serum and exposed to angiotensin II (100 nM for 6 h). NADPH oxidase activity was assessed by a novel spectrofluorometric assay for dihydroethidium oxidation products (31) in the absence or presence of PDI inhibitors DTNB (500 μ M) and neutralizing anti-PDI antibody (1:100), added to membrane homogenates ($n = 3$; * $p < 0.05$ vs. control baseline; # $p < 0.05$ vs. control + AII; mean \pm SEM).

role in cardiovascular diseases, particularly atherosclerosis and hypertension (16, 99).

Altogether, such data indicate that a regulatory effect for PDI appears to constitute a more general property of the NADPH oxidase family rather than a peculiar finding of the VSMC.

MECHANISMS UNDERLYING PDI-MEDIATED NADPH OXIDASE REGULATION

The mechanisms underlying PDI-mediated regulation of NADPH oxidase remain speculative. Despite this fact, some hypotheses and inferences based on the several known properties of PDI can be made at this point.

The results obtained in vascular cell membrane homogenates incubated with exogenous NADPH render it unlikely that changes in cell redox status or NADPH availability are major factors underlying PDI effects on the oxidase. Indeed, PDI does not exhibit characteristics of a redox buffer system, due to its oxidase properties and compartmentalization (74, 108).

Figure 8 depicts two conceptual models whereby PDI may associate with NADPH oxidase subunits and potentially modulate catalytic activity of the complex. The most intuitive model (Model I) predicts that PDI would associate with the oxidase through a direct disulfide exchange via the thioredoxin motif. However, the arguments supporting this model are weak or conflictive. First, typical thioredoxin motifs are absent among known vascular cell catalytic and regulatory oxidase subunits, according to detailed database searches. Still, at least one regulatory dithiol has been postulated for Nox2 as the binding site of phenylarsine oxide (23), and four cysteines have been described in the p47phox molecule (44). In addition, as discussed above, PDI binding to other proteins, including one or more putative oxidase subunits, usually does not require the thioredoxin

motifs, and occurs mainly as a hydrophobic interaction at or close to the b' domain (53, 73, 98, 108). Even for other PDI family proteins such as Erp57, PDI binding does not involve PDI thioredoxin domain (52). The thioredoxin motifs, however, are important for subsequent stabilization of substrate binding to PDI. Such considerations implicate Model II as a more plausible, although less defined, alternative. In this model, PDI would bind to any oxidase-related subunit via its hydrophobic domain(s), and the redox-dependent part of PDI effects would involve disulfide exchange with another yet undisclosed dithiol motif, which could belong to any (co-)regulatory, structural or thioredoxin family-related protein.

Possible ways whereby PDI assists the oxidase complex likely reflect one or more of its versatile functions. First, PDI could contribute to stabilization of the binding among one or more subunits of the complex. Such a role is consistent with PDI chaperone and/or redox activities. In fact, protein complex stabilization has been increasingly recognized as one of the main functions of chaperones, in addition to their assis-





FIG. 7. Close association between PDI and human neutrophil NADPH oxidase subunits. Membrane and cytosolic fractions from neutrophils stimulated (+) or not (–) with phorbol myristate acetate (PMA, 0.1 μ g/ml, 12 min) were prepared by nitrogen cavitation, followed by centrifugation through a Percoll gradient. (A) Neutrophil membranes were submitted to immunoprecipitation (IP) with anti-PDI antibody, followed by Western blot analysis (WB) using anti-p22phox or anti-PDI antibodies. (B) Neutrophil membrane or cytosolic fraction was submitted to IP with anti-PDI antibody, followed by WB using anti-p47phox or anti-p67phox antibodies, as indicated. Antibody sources (all dilutions 1:1,000) – PDI: Affinity Bioreagents; p22phox: kind gift from M. Quinn, U. Montana; p47phox and p67phox: Upstate or kind gift from B. Babior, Scripps RI, La Jolla.

FIG. 8. Two conceptual models for PDI interaction with NADPH oxidase subunits, based on known structure and properties of PDI. In this diagram, Nox stands for one or more of the catalytic or regulatory subunits. The PDI redox configurations corresponding to active and inactive oxidase are unknown at present. In Model II, the redox status of oxidase-bound PDI thiols is only one of the possible hypothesis. For clarity, only one PDI dithiol is shown. In Model I, a possible mixed disulfide intermediate between PDI and Nox subunit is not represented.



tance in intramolecular folding (26). Second, given its known association with intracellular traffic, PDI could also contribute to deliver, stabilize binding, or remove specific Nox subunits from microdomains, thereby allowing the temporospatial control of localized ROS production. Finally, PDI might contribute to target specific oxidase subunits for proteolytic degradation, in line with its known role in endoplasmic reticulum-associated protein degradation by the proteasome (71, 91, 92).

Although redox pathways appear to be involved in PDI-mediated effects on NADPH oxidase, a more precise picture is yet undefined. The overall reducing redox ambient outside of the ER is consistent with PDI preferentially acting as a reductase at such locations. Indeed, labeling studies indicate that the presence of PDI at the cell surface is associated with reduction of most cell surface thiols, although a minority is oxidized (47). In addition, a thiol reducing effect of PDI at the platelet surface underlies its effect on integrin-mediated adhesion and aggregation (12), whereas trans-nitrosation underlies PDI-mediated disabling of tissue factor procoagulant effect (1). With the exception of Nox4, which may at least in some instances be located in the ER (69), Nox catalytic subunit locations include preferentially endosomes, caveolae, plasma membrane, or focal adhesions (105). Thus, a similar redox profile of PDI concerning its association with oxidase subunits might be anticipated. However, in this case, the exposure to ROS confined to a microvesicular environment [*e.g.*, an endosome (65)], could convert PDI into a thiol oxidase/isomerase. In fact, the low pKa of the exposed N-terminal cysteine of WCGHC motif renders PDI a preferential target of hydrogen peroxide-mediated oxidation (51) or glutathiolation (35). On the other hand, the acidic pH in the range of that found in secretory vesicles tends to increase the half-time of PDI-mediated substrate oxidation (2, 85). Thus, the redox profile of PDI accompanying its interaction with NADPH oxidase may be complex or diversified.

It is important to note that the limited data available so far do not allow establishing how specific the regulation of the oxidase by PDI might be. Given the abundant PDI expression and its multiple functions, as well as the fact that several other proteins are affected by thiol redox, including nitric oxide synthase (94) and xanthine oxidase (13), it would not be unexpected that PDI or analogous proteins exert a similar regulatory role in other

enzyme systems. However, both for phagocytic and non-phagocytic oxidases, specificity is clearly not a prerequisite for relevance, considering, for example, that the subunit *rac*, well known to play an important regulatory role for the oxidase (39), also exerts many additional unrelated cellular functions. Conversely, the report that EFP1, a novel PDI-homologue of the thioredoxin superfamily, associates with Duox proteins of the Nox family as a component of the assembled membrane complex (107) raises the possibility that other PDI family members may also be involved with NADPH oxidase proteins. Finally, the available data do not allow to exclude that NAD(P)H oxidase might conversely exert a regulatory role on some of the multiple PDI functions. In this context, the reported association of PDI with wild-type SOD1 protein in neuronal cells (6) adds further complexity to such pathways.

TOWARDS AN INTEGRATIVE VIEW OF NADPH OXIDASE REGULATION

Although essential questions regarding PDI–NADPH oxidase interaction remain yet to be clarified, it can be anticipated that the nature of PDI effects discussed in the present review will provide novel avenues to allow a more integrative view of how NADPH oxidase is controlled in pathophysiological conditions. First, results of experiments with VSMC or endothelial membrane homogenates suggest that PDI is probably involved in mechanisms associated with a redox-mediated on-off switch of the oxidase at local membrane domains (Figs. 3 and 6). Second, the interaction with PDI can help understand mechanisms related to processing and/or traffic of Nox subunits between the ER and distal compartments of the secretory pathway. The involvement with PDI highlights the ER-secretory pathway as an important, if not the main, scenario in which NADPH oxidase is activated and exerts its signaling functions. Finally, perhaps one of the most interesting implications of the interaction with PDI is the possibility that knowledge of the intricate role of PDI in cellular physiology allows better understanding of the cell (patho)physiology of NADPH oxidase-dependent oxidative stress. Indeed, ongoing studies from our laboratory suggest that PDI–NADPH oxidase interaction may contribute to bridge UPR/endoplasmic reticulum

stress to oxidative stress, possibly in the context of an integrated adaptive stress response. This physiological connection may have implications regarding vascular response to injury (CX Santos *et al.*, unpublished observations).

In summary, the novel role of PDI discussed in this review is likely to integrate with several other advances in the knowledge of NADPH oxidase control mechanisms, contributing to a more detailed model of how such enzymatic complex is regulated in vascular diseases. Clearly, this knowledge is essential to improve the accuracy and pathophysiological significance of current paradigms of redox signaling. Moreover, understanding how ROS are produced provides novel pathways for rational interventions aimed at controlling their generation in vascular diseases, an approach so far neglected in favor of interventions aimed at removing ROS after they are formed.

ACKNOWLEDGMENTS

Work supported by grants from FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico)—Instituto do Milênio *Redoxoma*, and FINEP (Financiadora de Estudos e Projetos). DCF and AMA are supported by FAPESP.

ABBREVIATIONS

ALS, amyotrophic lateral sclerosis; DTNB, 5,5' dithio-bis (2-nitrobenzoic) acid; EPR, electron paramagnetic resonance; ER, endoplasmic reticulum; Ero-1, Endoplasmic reticulum oxidase-1; FRET, fluorescence resonance energy transfer; GSH, reduced glutathione; GSSG, oxidized glutathione; PCMPS, p-chloro mercuriphenylsulfonic acid; PDI, protein disulfide isomerase; ROS, reactive oxygen species; SOD1, Cu,Zn-superoxide dismutase; UPR, unfolded protein response; VSMC, vascular smooth muscle cells.

REFERENCES

- Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, and Ruf W. Disulfide isomerization switches tissue factor from coagulation to cell signaling. *Proc Natl Acad Sci USA* 103: 13932–13937, 2006.
- Alanen HI, Salo KE, Pirneskoski A, and Ruddock LW. pH dependence of the peptide thiol-disulphide oxidase activity of six members of the human protein disulphide isomerase family. *Antioxid Redox Signal* 8: 283–291, 2006.
- Alvarez B, Ferrer-Sueta G, Freeman BA, and Radi R. Kinetics of peroxynitrite reaction with amino acids and human serum albumin. *J Biol Chem* 274: 842–848, 1999.
- Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, and Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. *J Biol Chem* 279: 45935–45941, 2004.
- Arrigo AP. Gene expression and the thiol redox state. *Free Radical Biol Med* 27: 936–944, 1999.
- Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, Nunan J, Rembach A, Nagley P, Beart PM, Cheema SS, and Horne MK. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. *J Biol Chem* 281: 30152–30165, 2006.
- Barbouche R, Miquelis R, Jones IM, and Fenouillet E. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. *J Biol Chem* 278: 3131–3136, 2003.
- Bellavite P, Cross AR, Serra MC, Davoli A, and Jones OTG. The cytochrome *b* and flavin content and properties of the O₂^{•-}-forming NADPH oxidase solubilized from activated neutrophils. *Biochim Biophys Acta* 746: 40–47, 1983.
- Bennett TA, Edwards BS, Sklar LA, and Rogelj S. Sulfhydryl regulation of L-selectin shedding: phenylarsine oxide promotes activation-independent L-selectin shedding from leukocytes. *J Immunol* 164: 4120–4129, 2000.
- Bielski BHJ and Shiue GG. Oxygen Free Radicals and Tissue Damage, Ciba Foundation Symposium 65 (New Series), Excerpta Medica, New York, p. 43–56, 1979.
- Brandes RP and Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. *Cardiovasc Res* 65: 16–27, 2005.
- Burgess JK, Hotchkiss KA, Suter C, Dudman NP, Szollosi J, Chesterman CN, Chong BH, and Hogg PJ. Physical proximity and functional association of glycoprotein 1b α and protein-disulfide isomerase on the platelet plasma membrane. *J Biol Chem* 275: 9758–9766, 2000.
- Cabre F, Cascante M, and Canela EI. The molybdoenzymes xanthine oxidase and aldehyde oxidase contain fast- and slow-DTNB reacting sulphhydryl groups. *J Protein Chem* 11: 547–551, 1992.
- Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, and Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. *Biochemistry* 42: 9906–9914, 2003.
- Catz SD, Johnson JL, and Babior BM. The C2A domain of JFC1 binds to 3'-phosphorylated phosphoinositides and directs plasma membrane association in living cells. *Proc Natl Acad Sci USA* 99: 11652–11657, 2002.
- Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, and Shah AM. NADPH oxidases in cardiovascular health and disease. *Antioxid Redox Signal* 8: 691–728, 2006.
- Clempus R and Griendling KK. Reactive oxygen signaling in vascular smooth muscle cells. *Cardiovasc Res* 71: 216–225, 2006.
- Clissold PM and Bicknell R. The thioredoxin-like fold: hidden domains in protein disulfide isomerases and other chaperone proteins. *Bioessays* 25: 603–611, 2003.
- Colston JT, de la Rosa SD, Strader JR, Anderson MA, and Freeman GL. H₂O₂ activates Nox4 through PLA2-dependent arachidonic acid production in adult cardiac fibroblasts. *FEBS Lett* 579: 2533–2540, 2005.
- Cross AR. Inhibitors of the leukocyte superoxide generating oxidase: Mechanisms of action and methods for their elucidation. *Free Radical Biol Med* 8: 71–93, 1990.
- Delom F, Mallet B, Carayon P, and Lejeune PJ. Role of extracellular molecular chaperones in the folding of oxidized proteins. Refolding of colloidal thyroglobulin by protein disulfide isomerase and immunoglobulin heavy chain-binding protein. *J Biol Chem* 276: 21337–21342, 2001.
- Desjardins M. ER-mediated phagocytosis: a new membrane for new function. *Nat Rev Immunol* 3: 280–291, 2003.
- Donoghue N, Yam, PTW, Jiang X-M, and Hogg PJ. Presence of closely spaced protein thiols on the surface of mammalian cells. *Protein Sci* 9: 2436–2445, 2000.
- Doussiere J, Poinas A, Blais C, and Vignais PV. Phenylarsine oxide as an inhibitor of the activation of the neutrophil NADPH oxidase—identification of the beta subunit of the flavocytochrome b component of the NADPH oxidase as a target site for phenylarsine oxide by photoaffinity labeling and photoinactivation. *Eur J Biochem* 251: 649–658, 1998.
- Djordjevic T, Pogrebniak A, BelAiba RS, Bonello S, Wotzlaw C, Acker H, Hess J, and Grollach A. The expression of the NADPH oxidase subunit p22phox is regulated by a redox-sensitive pathway in endothelial cells. *Free Radical Biol Med* 38: 616–630, 2005.

25. Ellgaard L and Ruddock LW. The human protein disulphide isomerase family: substrate interactions and functional properties. *EMBO Rep* 6: 28–32, 2005.
26. Ellis RJ. Molecular chaperones: assisting assembly in addition to folding. *Trends Biochem Sci* 31: 395–401, 2006.
27. Eschenlauer SC and Page AP. The Caenorhabditis elegans ERp60 homolog protein disulfide isomerase-3 has disulfide isomerase and transglutaminase-like cross-linking activity and is involved in the maintenance of body morphology. *J Biol Chem* 278: 4227–4237, 2003.
28. Essex DW, Chen K, and Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. *Blood* 86: 2168–2173, 1995.
29. Essex DW, Li M, Miller A, and Feinman RD. Protein disulfide isomerase and sulphydryl-dependent pathways in platelet activation. *Biochemistry* 40: 6070–6075, 2001.
30. Ferrari DM and Soling HD. The protein disulphide-isomerase family: unravelling a string of folds. *Biochem J* 339: 1–10, 1999.
31. Fernandes DC, Wosniak J, Pescatore LA, Bertoline MA, Liberman M, Laurindo FR, and Santos CX. Analysis of DHE-derived oxidation products by HPLC in the assessment of superoxide production and NADPH oxidase activity in vascular systems. *Am J Physiol Cell Physiol* 292: C413–C422, 2007.
32. Forman HJ, Fukuto JM, and Torres M. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. *Am J Physiol Cell Physiol* 287: C246–C256, 2004.
33. Forster ML, Sivick K, Park YN, Arvan P, Lencer WI, and Tsai B. Protein disulfide isomerase-like proteins play opposing roles during retrotranslocation. *J Cell Biol* 173: 853–859, 2006.
34. Frand AR, Cuozzo JW, and Kaiser CA. Pathways for protein disulphide bond formation. *Trends Cell Biol* 10: 203–210, 2000.
35. Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmons M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vandekerckhove J, Gianazza E, and Ghezzi P. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. *Proc Natl Acad Sci USA* 99: 3505–3510, 2002.
36. Gallina A, Hanley TM, Mandel R, Trahey M, Broder CC, Viglianti GA, and Ryser HJ. Inhibitors of protein–disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. *J Biol Chem* 277: 50579–50588, 2002.
37. Go YM, Gipp JJ, Mulcahy RT, and Jones DP. H₂O₂-dependent activation of GCLC-ARE4 reporter occurs by mitogen-activated protein kinase pathways without oxidation of cellular glutathione or thioredoxin-1. *J Biol Chem* 279: 5837–5845, 2004.
38. Graven KK, Molvar C, Roncarati JS, Klahn BD, Lowrey S, and Farber HW. Identification of protein disulfide as endothelial hypoxic stress protein. *Am J Physiol Lung Cell Mol Physiol* 282: L996–L1003, 2002.
39. Griendling KK, Sorescu D, and Ushio–Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. *Circ Res* 86: 494–501, 2000.
40. Gross E, Sevier CS, Heldman N, Vitu E, Bentzur M, Kaiser CA, Thorpe C, and Fass D. Generating disulfides enzymatically: Reaction products and electron acceptors of the endoplasmic reticulum thiol oxidase Ero1p. *Proc Natl Acad Sci USA* 103: 299–304, 2006.
41. Gruber CW, Cemazar M, Heras B, Martiin JL, and Craik DJ. Protein disulfide isomerase: the structure of oxidative folding. *Trends Biochem Sci* 31: 455–464, 2006.
42. Guthapfel R, Gueguen P, and Quemeneur E. ATP binding and hydrolysis by the multifunctional protein disulfide isomerase. *J Biol Chem* 271: 2663–2666, 1996.
43. Huang EM, Detwiler TC, Milev Y, and Essex DW. Thiol-disulfide isomerization in thrombospondin: effects of conformation and protein disulfide isomerase. *Blood* 89: 3205–3212, 1997.
44. Inanami O, Johnson JL, and Babior BM. The leukocyte NADPH oxidase subunit p47PHOX: the role of the cysteine residues. *Arch Biochem Biophys* 350: 36–40, 1998.
45. Janiszewski M, Pedro MA, Scheffer RC, van Asseldonk JH, Souza LC, da Luz PL, Augusto O, and Laurindo FR. Inhibition of vascular NADH/NADPH oxidase activity by thiol reagents: lack of correlation with cellular glutathione redox status. *Free Radical Biol Med* 29: 889–899, 2000.
46. Janiszewski M, Lopes LR, Carmo AO, Pedro MA, Brandes RP, Santos CX, and Laurindo FR. Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. *J Biol Chem* 280: 40813–40819, 2005.
47. Jiang XM, Fitzgerald M, Grant CM, and Hogg PJ. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. *J Biol Chem* 274: 2416–2423, 1999.
48. John DC, Grant ME, and Bulleid NJ. Cell-free synthesis and assembly of prolyl 4-hydroxylase: the role of the beta-subunit (PDI) in preventing misfolding and aggregation of the alpha-subunit. *EMBO J* 12: 1587–1595, 1993.
49. Jones DP. Redefining oxidative stress. *Antiox Redox Signal* 8: 1865–1879, 2006.
50. Kaufmann BB and van Ourdenaarden A. Stochastic gene expression: from single molecules to the proteome. *Curr Opin Genet Dev* 17: 107–112, 2007.
51. Kim JR, Yoon HW, Kwon KS, Lee SR, and Rhee SG. Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH. *Anal Biochem* 283: 214–221, 2000.
52. Kimura T, Imaishi K, Hagiwara Y, Horibe T, Hayano T, Takahashi N, Urade R, Kato K, and Kikuchi M. ERp57 binds competitively to protein disulfide isomerase and calreticulin. *Biochem Biophys Res Commun* 331: 224–230, 2005.
53. Klappa P, Hawkins HC, and Freedman RB. Interactions between protein disulphide isomerase and peptides. *Eur J Biochem* 248: 37–42, 1997.
54. Kobayashi T, Robinson JM, and Seguchi H. Identification of intracellular sites of superoxide production in stimulated neutrophils. *J Cell Sci* 111: 81–91, 1998.
55. Koivunem P, Salo KEH, Myllyharju J, and Ruddock LW. Three binding sites in protein disulfide isomerase cooperate in collagen prolyl 4-hydroxylase tetramer assembly. *J Biol Chem* 280: 5227–5235, 2005.
56. Kulp MS, Frickel EM, Ellgaard L, and Weissman JS. Domain architecture of protein-disulfide isomerase facilitates its dual role as an oxidase and an isomerase in Ero1p-mediated disulfide formation. *J Biol Chem* 281: 876–884, 2006.
57. Laboissiere MC, Sturley SL, and Raines RT. The essential function of protein-disulfide isomerase is to unscramble non-native disulfide bonds. *J Biol Chem* 270: 28006–28009, 1995.
58. Lahav J, Gofer–Dadosh N, Luboshitz J, Hess O, and Shalkai M. Protein disulfide isomerase mediates integrin-dependent adhesion. *FEBS Lett* 475: 89–92, 2000.
59. Lahav J, Jurk K, Hess O, Barnes MJ, Farndale RW, Luboshitz J, and Kehrel BE. Sustained integrin ligation involves extracellular free sulphydryls and enzymatically catalyzed disulfide exchange. *Blood* 100: 2472–2478, 2002.
60. Lahav J, Wijnen EM, Hess O, Hamaia SW, Griffiths D, Makris M, Knight CG, Essex DW, and Farndale RW. Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. *Blood* 102: 2085–2092, 2003.
61. Langenbach KJ and Sottile J. Identification of protein-disulfide isomerase activity in fibronectin. *J Biol Chem* 274: 7032–7038, 1999.
62. Lappi AK, Lensink MF, Alanen HI, Salo KE, Lobell M, Juffer AH, and Ruddock LW. A conserved arginine plays a role in the catalytic cycle of the protein disulphide isomerases. *J Mol Biol* 335: 283–295, 2004.
63. Lassegue B and Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. *Am J Physiol Regul Integr Comp Physiol* 285: R277–297, 2003.
64. Li JM and Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. *J Biol Chem* 278: 12094–12100, 2003.
65. Li Q, Harraz MM, Zhou W, Zhang LN, Ding W, Zhang Y, Eggleston T, Yeaman C, Banfi B, and Engelhardt JF. Nox2 and Rac1

- regulate H₂O₂-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. *Mol Cell Biol* 26: 140–154, 2006.
66. Li WG, Miller Jr FJ, Zhang HJ, Spitz DR, Oberley LW, and Weintraub NL. H₂O₂-induced O₂^{•−} production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. *J Biol Chem* 276: 29251–29256, 2001.
 67. Lundstrom J, Krause G, and Holmgren A. A Pro to His mutation in active site of thioredoxin increases its disulfide-isomerase activity 10-fold. New refolding systems for reduced or randomly oxidized ribonuclease. *J Biol Chem* 267: 9047–9052, 1992.
 68. Mandel R, Ryser HJ, Ghani F, Wu M, and Peak D. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. *Proc Natl Acad Sci USA* 90: 4112–4116, 1993.
 69. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. *Cell Signal* 18: 69–82, 2006.
 70. Meunier L, Usherwood YK, Chung KT, and Hendershot LM. A subset of chaperones and folding enzymes form multiprotein complexes in endoplasmic reticulum to bind nascent proteins. *Mol Biol Cell* 13: 4456–4469, 2002.
 71. Meusser B, Hirsch C, Jarosch E, and Sommer T. ERAD: the long road to destruction. *Nat Cell Biol* 7: 766–772, 2005.
 72. Molteni SN, Fassio A, Ciriolo MR, Filomeni G, Pasqualetto E, Fagioli C, and Sitia R. Glutathione limits Ero1-dependent oxidation in the endoplasmic reticulum. *J Biol Chem* 279: 32667–32673, 2004.
 73. Noiva R, Freedman RB, and Lennarz WJ. Peptide binding to protein disulfide isomerase occurs at a site distinct from the active sites. *J Biol Chem* 268: 19210–19217, 1993.
 74. Noiva R. Protein disulfide isomerase: the multifunctional redox chaperone of the endoplasmic reticulum. *Semin Cell Dev Biol* 10: 481–493, 1999.
 75. O'Neill S, Robinson A, Deering A, Ryan M, Fitzgerald DJ, and Moran N. The platelet integrin alpha IIb beta 3 has an endogenous thiol isomerase activity. *J Biol Chem* 275: 36984–36990, 2000.
 76. Orlandi PA. Protein-disulfide isomerase-mediated reduction of the A subunit of cholera toxin in a human intestinal cell line. *J Biol Chem* 272: 4591–4599, 1997.
 77. Otsu M, Bertoli G, Fagioli C, Guerini-Rocco E, Nerini-Molteni S, Ruffato E, and Sitia R. Dynamic retention of Ero1alpha and Ero1beta in the endoplasmic reticulum by interactions with PDI and ERp44. *Antioxid Redox Signal* 8: 274–282, 2006.
 78. Pariser HP, Zhang J, and Hausman RE. The cell adhesion molecule retina cognin is a cell surface protein disulfide isomerase that uses disulfide exchange activity to modulate cell adhesion. *Exp Cell Res* 258: 42–52, 2000.
 79. Park B, Lee S, Kim E, Cho K, Riddell SR, Cho S, and Ahn K. Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. *Cell* 127: 369–382, 2006.
 80. Plonka A, Krasiukianis R, Mayer J, Zgierski A, and Hilewicz-grabska M. Pulse-radiolysis studies on reactivity of BSA and BSA-Cu(II) complexes. *Radiation Physics Chem* 38: 445–447, 1991.
 81. Radi R, Beckman JS, Bush KM, and Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. *J Biol Chem* 266: 4244–4250, 1991.
 82. Ramachandran N, Root P, Jiang XM, Hogg PJ, and Mutus B. Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulfide isomerase. *Proc Natl Acad Sci USA* 98: 9539–9544, 2001.
 83. Rao ASK and Hausman RE. cDNA for R-cognin: homology with a multifunctional protein. *Proc Natl Acad Sci USA* 90: 2950–2954, 1993.
 84. Rocic P, Seshiah P, and Griendling KK. Reactive oxygen species sensitivity of angiotensin II-dependent translation initiation in vascular smooth muscle cells. *J Biol Chem* 278: 36973–36979, 2003.
 85. Ruddock LW, Hirst TR, and Freedman RB. PH-dependence of the dithiol-oxidizing activity of DsbA (a periplasmic protein thiol:disulphide oxidoreductase) and protein disulphide-isomerase: studies with a novel simple peptide substrate. *Biochem J* 315: 1001–1005, 1996.
 86. Rutkowski DT and Kaufman RJ. A trip to the ER: coping with stress. *Trends Cell Biol* 14: 20–28, 2004.
 87. Saloheimo M, Lund M, and Penttila ME. The protein disulphide isomerase gene of the fungus *Trichoderma reesei* is induced by endoplasmic reticulum stress and regulated by the carbon source. *Mol Gen Genet* 262: 35–45, 1999.
 88. Sekaki A, Gardes-Albert M, and Ferradini C. Aspects physico-chimiques des espèces réactives de l'oxygène. *Journ Etude Chim Radiat Societe Francaise de Chimie*, Mont Sainte-Odile, France, 1984.
 89. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. *Circ Res* 91: 406–413, 2002.
 90. Shoulders CC and Shelness GS. Current biology of MTP: implications for selective inhibition. *Curr Top Med Chem* 5: 283–300, 2005.
 91. Sitia R, Braakman I. Sitia R, and Braakman I. Quality control in the endoplasmic reticulum protein factory. *Nature* 426: 891–894, 2003.
 92. Sitia R and Molteni SN. Stress, protein (mis)folding, and signaling: the redox connection. *Sci STKE* 239: 27, 2004.
 93. Stockton JD, Merkert MC, and Kellaris KV. A complex of chaperones and disulfide isomerases occludes the cytosolic face of the translocation protein Sec61p and affects translocation of the prion protein. *Biochemistry* 42: 12821–12834, 2003.
 94. Su Y and Block ER. Phenylarsine oxide inhibits nitric oxide synthase in pulmonary artery endothelial cells. *Free Radical Biol Med* 28: 167–173, 2000.
 95. Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulosom R, Creamer D, Barker J, and Bicknell R. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. *J Biol Chem* 278: 47079–47088, 2003.
 96. Tanaka S, Uehara T, and Nomura Y. Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. *J Biol Chem* 275: 10388–10393, 2000.
 97. Terada K, Manchikalapudi P, Noiva R, Jauregui HO, Stockert RJ, and Schilsky ML. Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. *J Biol Chem* 270: 20410–20416, 1995.
 98. Tian G, Xiang S, Noiva R, Lennarz WJ, and Schindelin H. The crystal structure of yeast protein disulfide isomerase suggests cooperativity between its active sites. *Cell* 124: 61–73, 2006.
 99. Touyz RM, Tabet F, and Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. *Clin Exper Pharmacol Physiol* 30: 860–866, 2003.
 100. Touyz RM, Yao G, and Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 23: 981–987, 2003.
 101. Tu BP and Weissman JS. The FAD- and O(2)-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum. *Mol Cell* 10: 983–994, 2002.
 102. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, and Lipton SA. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. *Nature* 441: 513–517, 2006.
 103. Ueyama T, Lekstrom K, Tsujibe S, Saito N, and Leto TL. Subcellular localization and function of alternatively spliced Nox1 isoforms. *Free Radical Biol Med* 42: 180–190, 2007.
 104. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, and Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. *J Biol Chem* 274: 22699–22704, 1999.
 105. Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. *Sci STKE* 349(8): 1–6, 2006.
 106. Walsh GM, Sheehan D, Kinsella A, Moran N, and O'Neill S. Redox modulation of integrin [correction of integrin] alpha IIb beta

- 3 involves a novel allosteric regulation of its thiol isomerase activity. *Biochemistry* 43: 473–480, 2004.
107. Wang D, De Deken X, Milenkovic M, Song Y, Pirson I, Dumont JE, and Miot F. Identification of a novel partner of duox: EFP1, a thioredoxin-related protein. *J Biol Chem* 280: 3096–3103, 2005.
108. Wilkinson B and Gilbert HF. Protein disulfide isomerase. *Biochim Biophys Acta* 1699: 35–44, 2004.
109. Winterbourn CC and Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. *Free Radical Biol Med* 27: 322–328, 1999.
110. Yamawaki H, Haendeler J, and Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. *Circ Res* 93: 1029–1033, 2003.
111. Zai A, Rudd MA, Scribner AW, and Loscalzo J. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. *J Clin Invest* 103: 393–399, 1999.

Address reprint requests to:
Francisco R. M. Laurindo
Vascular Biology Laboratory
Heart Institute (InCor)
University of São Paulo School of Medicine
Av Eneas C Aguiar, 44, Annex II, 9th floor
CEP 05403-000
São Paulo, Brazil

E-mail: expfrancisco@incor.usp.br

Date of first submission to ARS Central, December 8, 2007;
date of acceptance, December 8, 2007.

This article has been cited by:

1. Eberhard Schulz , Philip Wenzel , Thomas Münzel , Andreas Daiber . Mitochondrial Redox Signaling: Interaction of Mitochondrial Reactive Oxygen Species with Other Sources of Oxidative Stress. *Antioxidants & Redox Signaling*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2. Francisco R.M. Laurindo, Luciana A. Pescatore, Denise de Castro Fernandes. 2012. Protein disulfide isomerase in redox cell signaling and homeostasis. *Free Radical Biology and Medicine* **52**:9, 1954-1969. [[CrossRef](#)]
3. Claudia R. Andrade, Beatriz S. Stolf, Victor Debbas, Daniela S. Rosa, Jorge Kalil, Veronica Coelho, Francisco R. M. Laurindo. 2011. Quiescin sulfhydryl oxidase (QSOX) is expressed in the human atheroma core: possible role in apoptosis. *In Vitro Cellular & Developmental Biology - Animal* . [[CrossRef](#)]
4. Irena Szumiel. 2011. Autophagy, reactive oxygen species and the fate of mammalian cells. *Free Radical Research* **45**:3, 253-265. [[CrossRef](#)]
5. Beatriz S. Stolf, Ioannis Smyrniak, Lucia R. Lopes, Alcione Vendramin, Hiro Goto, Francisco R. M. Laurindo, Ajay M. Shah, Celio X. C. Santos. 2011. Protein Disulfide Isomerase and Host-Pathogen Interaction. *The Scientific World JOURNAL* **11**, 1749-1761. [[CrossRef](#)]
6. Yong-Cheng Jin, Hong-Gu Lee, Cheng-Xiong Xu, Jeng-A Han, Seong-Ho Choi, Man-Kang Song, Young-Jun Kim, Ki-Beom Lee, Seon-Ku Kim, Han-Seok Kang, Byung-Wook Cho, Teak-Soon Shin, Yun-Jaie Choi. 2010. Proteomic analysis of endogenous conjugated linoleic acid biosynthesis in lactating rats and mouse mammary gland epithelia cells (HC11). *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics* **1804**:4, 745-751. [[CrossRef](#)]
7. Célio X.C. Santos , Leonardo Y. Tanaka , João Wosniak , Jr. , Francisco R.M. Laurindo . 2009. Mechanisms and Implications of Reactive Oxygen Species Generation During the Unfolded Protein Response: Roles of Endoplasmic Reticulum Oxidoreductases, Mitochondrial Electron Transport, and NADPH Oxidase. *Antioxidants & Redox Signaling* **11**:10, 2409-2427. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental material](#)]
8. Srikanth Pendyala , Peter V. Usatyuk , Irina A. Gorshkova , Joe G.N. Garcia , Viswanathan Natarajan . 2009. Regulation of NADPH Oxidase in Vascular Endothelium: The Role of Phospholipases, Protein Kinases, and Cytoskeletal Proteins. *Antioxidants & Redox Signaling* **11**:4, 841-860. [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
9. Denise C. Fernandes, Ana Heloisa O. Manoel, João Wosniak, Francisco R. Laurindo. 2009. Protein disulfide isomerase overexpression in vascular smooth muscle cells induces spontaneous preemptive NADPH oxidase activation and Nox1 mRNA expression: Effects of nitrosothiol exposure. *Archives of Biochemistry and Biophysics* **484**:2, 197-204. [[CrossRef](#)]
10. Savita Khanna , Han-A Park , Chandan K. Sen , Trimurtulu Golakoti , Krishanu Sengupta , Somepalli Venkateswarlu , Sashwati Roy . 2009. Neuroprotective and Antiinflammatory Properties of a Novel Demethylated Curcuminoid. *Antioxidants & Redox Signaling* **11**:3, 449-468. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
11. Mona Sedeek, Richard L Hébert, Chris R Kennedy, Kevin D Burns, Rhian M Touyz. 2009. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. *Current Opinion in Nephrology and Hypertension* **18**:2, 122-127. [[CrossRef](#)]